SCARA5: A Protein Targeted for Neurodegenerative Diseases (G286133)

Target Name: SCARA5

NCBI ID: G286133

SCARA5

SCARA5: A Protein Targeted for Neurodegenerative Diseases

SCARA5 ( Short for Syntax-Constrained Adaptive Responsiveness-Adaptive) is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's. The protein is also being targeted as a potential drug target.

SCARA5 is a member of the SCARA family of proteins, which are known for their ability to generate complex, highly ordered structures in response to various environmental inputs, such as changes in temperature or mechanical forces. The SCARA5 protein is unique in that it is able to adapt to these changes in a highly responsive manner, allowing it to respond quickly and accurately to different stimuli.

One of the key features of SCARA5 is its ability to undergo a conformational change, which allows it to alter its shape and properties in response to different stimuli. This conformational change is mediated by a protein called NET33, which is also a member of the SCARA family.

Research has shown that SCARA5 and NET33 are highly interconnected, and that changes in the expression or activity of either protein can have a significant impact on the function of the other. For example, studies have shown that increasing the level of NET33 in the brain can enhance the activity of SCARA5, while decreasing the level of NET33 can inhibit its activity.

This relationship between SCARA5 and NET33 makes them an attractive target for researchers who are interested in developing new treatments for neurodegenerative diseases. By targeting SCARA5 and NET33, researchers hope to be able to slow down or even reverse the progression of these diseases.

In addition to its potential as a drug target, SCARA5 is also being investigated as a biomarker for the early detection of neurodegenerative diseases. The protein is thought to be expressed in the brain and may be a useful indicator of the presence of neurodegenerate diseases, such as Alzheimer's and Parkinson's. This makes it an attractive target for researchers who are interested in developing new diagnostic tests for these diseases.

Overall, SCARA5 is a protein that is being studied for its potential as a drug target and biomarker for neurodegenerative diseases. Its unique ability to undergo conformational changes in response to different stimuli makes it an attractive target for researchers who are working to develop new treatments and diagnostic tests for these diseases.

Protein Name: Scavenger Receptor Class A Member 5

Functions: Ferritin receptor that mediates non-transferrin-dependent delivery of iron. Mediates cellular uptake of ferritin-bound iron by stimulating ferritin endocytosis from the cell surface with consequent iron delivery within the cell. Delivery of iron to cells by ferritin is required for the development of specific cell types, suggesting the existence of cell type-specific mechanisms of iron traffic in organogenesis, which alternatively utilize transferrin or non-transferrin iron delivery pathways. Ferritin mediates iron uptake in capsule cells of the developing kidney. Preferentially binds ferritin light chain (FTL) compared to heavy chain (FTH1)

The "SCARA5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARA5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets